Kepler Capital Sticks to Their Buy Rating for MaaT Pharma (MAAT)
Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on March 12 and set a price target of ...
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
Hosted on MSN2mon
Maat Pharma Phase III microbiome trial hits endpoints as stock soars
French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company ...
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013.
pharmaphorum8d
MaaT microbiota drug shows survival advantage in GvHD
MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).